KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Lecanemab for treatment of individuals with early Alzheimer's Disease (AD) who are apolipoprotein E ε4 (ApoE ε4) non-carriers or heterozygotes.

Richard Perry, Christopher Kipps, Maria Eugenia Soto Martín, Marco Bozzali, Giancarlo Logroscino, Sarah Trafford, Shobha Dhadda, Michio Kanekiyo, Amanda Goodwin, Mark Hodgkinson, Steven Hersch, Michael Irizarry, Lynn Kramer, Lutz Froelich

J Prev Alzheimers Dis 13(4) 100507

PMID41689888
PMCIDPMC12925093
DOI10.1016/j.tjpad.2026.100507
发表日期2026-02-14
入排依据:未发现恶性肿瘤人群证据。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 3 张 PMC Figure,均未识别为 KM 图:Fig. 1:图注未提示 KM 曲线;Fig. 2:图注未提示 KM 曲线;Fig. 3:图注未提示 KM 曲线。
摘要

摘要

BACKGROUND: Lecanemab, an antibody directed at Aβ-protofibrils and plaque, showed meaningful delay in disease progression and biological effects consistent with disease modification in the phase 3 Clarity AD trial. OBJECTIVE: The objective of this paper is to present efficacy and safety results in ApoE ε4 non-carriers or heterozygotes population of Clarity AD. DESIGN: Clarity AD is an 18-month, randomized study (core) in participants with early AD, with an open-label extension phase (OLE) phase. SETTING: Academic and clinical centers. PARTICIPANTS: All eligible ApoE ε4 participants were randomized 1:1 across 2 treatment groups (placebo and lecanemab 10 mg/kg biweekly); the results presented herein are for the ApoE4 heterozygote or non-carrier participants. MEASUREMENTS: Endpoints included change from baseline at 18 months in the global cognitive and functional scale, CDR-SB, amyloid positron emission tomography (PET), Alzheimer's Disease Assessment Scale-Cognitive Subscale 14 (ADAS-Cog14), Alzheimer's Disease Cooperative Study-Activities of Daily Living Scale for Mild Cognitive Impairment (ADCS-MCI-ADL), and health-related quality-of-life (HRQoL) assessments. Amyloid imaging related abnormalities (ARIA) occurrence was monitored throughout the study by central reading of magnetic resonance imaging. Following 18 months treatment in the Core, eligible participants transitioned to the OLE where they received open-label lecanemab. Clinical outcomes (CDR-SB, ADAS-Cog14, and ADCS-MCI-ADL) were evaluated by examining 'delayed start' (core:placebo followed by OLE:lecanemab) and 'early start' (core:lecanemab followed by OLE:lecanemab) cohorts as well as natural history cohorts. Time to progression to next stage of AD was also evaluated through 36 months. RESULTS: 1795 participants with early AD were enrolled in Clarity AD, of which 1521 were ApoE ε4 heterozygotes or non-carriers (85 %). Lecanemab significantly reduced clinical decline on CDR-SB at 18 months compared to placebo in the ApoEε4 heterozygotes or non-carriers subgroup. Amyloid PET, ADAS-Cog14, ADCS-MCI-ADL, and HRQoL results were consistent with the CDR-SB findings. In the analysis subgroup, the most common adverse reactions for lecanemab were infusion-related reactions (26 %), ARIA-H (13 %), fall (11 %), headache (11 %), and ARIA-E (9 %). In the OLE, lecanemab-treated participants continued to accrue benefit in CDR-SB through 36 months, with continued separation through 36 months relative to the ADNI natural history cohort. Delayed start results follow a parallel trajectory relative to early start results, but do not catch up, confirming a disease modifying effect and reflecting importance of early treatment initiation. Results were similar for ADAS-Cog14 and ADCS-MCI-ADL. Lecanemab reduced the risk of progression to next stage of AD by 28 % on lecanemab as compared to the ADNI natural history cohort. CONCLUSION: In the ApoE ε4 heterozygotes or non-carrier subgroup of Clarity AD, lecanemab slowed decline in disease progression and reduced markers of amyloid, with expanding benefit over time. GOV IDENTIFIER: Clarity AD NCT03887455.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(3,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 1Efficacy Endpoint Results: CDR-SB. A. CDR-SB by Standard MMRM Methodology (UK analysis population). B. CDR-SB by Control-Based Multiple Imputation Methodology (EU analysis population). C. Global CDR Time to Worsening Analysis. AD, Alzheimer’s disease. CDR, clinical dementia rating. CDR-SB, Clinical Dementia Rating - sum of boxes. CI, confidence interval. LS, least squares. MCI, mild cognitive impairment. SE, standard error. Note: Based on modified intention-to-treat analysis population. As requested by the European Medicines Agency regulatory authority, efficacy analyses were conducted for ApoE ε4 non-carriers or heterozygotes participants using control-based multiple imputation method, in which all missing values were imputed with copy-increments (change between visits) using the actual value in placebo group. This methodology differs from that used in the Clarity AD primary analysis which used mixed model for repeated measures (MMRM) with missing at random assumption.
非 KM Figure
Fig. 2Amyloid PET, ADAS-Cog14, and ADCS MCI-ADL Endpoint Results. A. Amyloid PET. After 18 months of treatment, the average amyloid level was 21 Centiloids in the lecanemab treatment group in the amyloid PET substudy, which is below the threshold for amyloid positivity of approximately 30 Centiloids above which participants are considered to have elevated brain amyloid. Note: Based on pharmacodynamic analysis population (amyloid PET sub-study population). PET: positron emission tomography. SE: standard error. B. ADAS-Cog14 by Standard MMRM Methodology (UK analysis population). C. ADAS-Cog14 by Control-Based Multiple Imputation Methodology (EU analysis population). Note: Based on modified intention-to-treat analysis population. As requested by the European Medicines Agency regulatory authority, efficacy analyses were conducted for ApoE ε4 non-carriers or heterozygotes participants using control-based multiple imputation method, in which all missing values were imputed with copy-increments (change between visits) using the actual value in placebo group. This methodology differs from that used in the Clarity AD primary analysis which used mixed model for repeated measures (MMRM) with missing at random assumption. ADAS-Cog14, Alzheimer’s Disease Assessment Scale–cognitive subscale. LS, least squares. SE, standard error. D. ADCS MCI-ADL by Standard MMRM Methodology (UK analysis population). E. ADCS MCI-ADL by Control-Based Multiple Imputation Methodology (EU analysis population). Note: Based on modified intention-to-treat analysis population. As requested by the European Medicines Agency regulatory authority, efficacy analyses were conducted for ApoE ε4 non-carriers or heterozygotes participants using control-based multiple imputation method, in which all missing values were imputed with copy-increments (change between visits) using the actual value in placebo group. This methodology differs from that used in the Clarity AD primary analysis which used mixed model for repeated measures (MMRM) with missing at random assumption. ADCS MCI-ADL, Alzheimer's Disease Cooperative Study-Activities of Daily Living Scale for Mild Cognitive Impairment. LS, least squares. SE, standard error.
非 KM Figure
Fig. 3ARIA-E Timing. AE, adverse event. ApoE4, apolipoprotein E4. ARIA, Amyloid related imaging abnormality. ARIA-E, ARIA with edema. ARIA-H, ARIA with haemosiderin deposits. MRI, magnetic resonance imaging. Overall population published in van Dyck CH, et al. N Engl J Med. 2023;388:9–21.
非 KM Figure